Penumbra, Inc. (PEN) fundamentals score
Penumbra, the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia.
Surgical & Medical Instruments & Apparatus · Healthcare · Listed on NYSE
Overall: 7.4 out of 10, Good long-term fundamentals
- Growth: 5.8/10
- Profitability: 7.5/10
- Financial health: 9.2/10
- Earnings quality: 8.6/10
- Valuation: 6.2/10
Scores are calculated from Penumbra, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10